u/Heavy_Snow2152

The topline results from the Phase 1b/2a trial were presented at the 2025 ASIA Annual Scientific Meeting.

It will be interesting to see if NervGen provides any update (either an oral presentation or poster) to the scientific community at the next ASIA conference in March 2027.

There has certainly been some impressive results that were released since the June, 2025 ASIA conference.

Also, NervGen should be in a good position to get these results published in a peer-reviewed journal within the coming months.

The deadline for abstract submission is August 1, 2026.

https://substack.com/home/post/p-206807666

https://antoniolinares.substack.com/p/they-were-paralyzed-then-they-joined

https://www.bioxconomy.com/modalities/breakthrough-peptide-repairs-nerves-after-spinal-cord-injury-in-clinical-trial

https://case.edu/news/how-one-school-medicine-researchers-legacy-offers-hope-those-spinal-cord-injuries

Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00.

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2118203/nervgen-pharma-ngen-receives-a-buy-from-stifel-nicolaus/

https://www.linkedin.com/posts/leerink-partners\_we-are-pleased-to-serve-as-lead-left-bookrunner-activity-7463637477392596995-GB49?utm\_source=share&utm\_medium=member\_ios&rcm=ACoAABMi7YcBmqvHPWZJJgMolCMtz72FbnC2cOw

At least it’s good to see some exposure of the company.

I hope Leerink Partners initiates coverage of NervGen with a decent price target.

The corporate presentation has been updated with the gait analysis results:

https://nervgen.com/wp-content/uploads/2026/05/NervGen-May-2026-Corporate-Presentation-for-Website-20260521_Non-Confidential-vFF.pdf

"Blinded biomechanical gait analyses were conducted by an independent party motion-specialist group, Newton Tech, with statistics validated by Cedars-Sinai. The analyses examined each participant in the NVG-291 and placebo arms (n=10 in each arm) from our Phase 1/2b CONNECT SCI study across the three biomechanical hallmarks of recovery: coordination, mechanical effort and postural stability. All NVG-291 participants exceeded the pairwise responder threshold across the hallmarks of recovery, compared to just one placebo participant (p = 0.00012). The independent analysis concluded that there was an approximate 73% probability that NVG-291 promoted genuine recovery based on the global statistical test (p = 0.0197), with a 95% confidence interval of the global treatment effect that excludes zero (+0.15, +0.72)."

These results are from the updated preliminary prospectus supplement (page S-12):

https://www.sec.gov/Archives/edgar/data/1751912/000110465926065185/tm2615031d1_suppl.htm#a_010

https://www.clinicaltrialvanguard.com/news/nervgen-prepares-restore-phase-3-trial-in-chronic-tetraplegia-with-nvg-291/

We are getting closer to starting the Phase 3. One of the Phase 3 trial locations in Atlanta.

https://shepherd.org/research-innovation/redefining-rehab/find-studies/nervegen-restore-phase-3/

https://www.biopharmadive.com/news/makary-fda-commissioner-resign-trump/819757/

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target.

The company is developing therapies for devastating neurological conditions, the analyst tells investors in a research note. The firm says NervGen’s lead candidate, NVG-291, is entering Phase 3 development for chronic tetraplegia in patients with incomplete cervical spinal cord injury. It believes the drug offers a “differentiated” mechanism based on key scientific principles.